Dow Jones Newswires: Novartis gets positive result from breast-cancer drug trial


Novartis AG said Monday that a trial evaluating breast-cancer drug Kisqali met its primary endpoint during an interim analysis.

The drug is shown to significantly reduce the risk of disease recurrence when used together with an endocrine therapy in patients with certain types of early breast cancers at risk of recurrence, the company said.

The Phase 3 trial, named Natalee, was stopped early as the primary endpoint has been met, Novartis NOVN, +5.87% NOVN, +5.87% said.

Write to Cecilia Butini at

This article was originally published by Read the original article here.

Previous articleFirst Citizens to acquire Silicon Valley Bridge Bank loans and deposits: FDIC
Next articleMarket Snapshot: U.S. stocks futures nudge higher as bank sector stress wanes


Please enter your comment!
Please enter your name here